01:54 AM EDT, 10/23/2026 (MT Newswires) -- Spago Nanomedical (SPAGO.ST) intends to delist its shares from the Nasdaq First North Growth Market to improve access to long-term financing for its cancer treatment candidate Tumorad. The Swedish nanomedicines company said Thursday that raising capital for a planned phase 2a trial on acceptable terms would be difficult while listed. The proposal requires shareholder approval at a Nov. 19 meeting, with holders of 65% of shares and votes having indicated their support. Spago expects to submit its delisting application no earlier than Jan. 25, 2027, with the last trading day anticipated in February 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.